This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
This transaction fundamentally strengthens Scinai's CDMO platform
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Subscribe To Our Newsletter & Stay Updated